Trials / Completed
CompletedNCT03519529
Sex Hormone Binding Globulin, Testosterone and Glycemic Control in Patients With Type 2 Diabetes
The Relationship Between Sex Hormone Binding Globulin, Testosterone and Glycemic Control in Patients With Type 2 Diabetes
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 250 (actual)
- Sponsor
- Nanjing First Hospital, Nanjing Medical University · Academic / Other
- Sex
- Male
- Age
- —
- Healthy volunteers
- Not accepted
Summary
Sex hormone-binding globulin(SHBG) is a surrogate marker of insulin resistance. This study aims at the characteristic and clinical significance of SHBG and testosterone in patients with type 2 diabetes(T2D).
Detailed description
The investigators recorded clinical factors, biochemical criterion such as serum levels of glucose and lipids, HbA1c, SHBG, testosterone, insulin, EPO, C-peptide, glucagon, microalbuminuria, glycemic variation via CGM, carotid plaque, ECG and ultrasonic cardiogram in patients with T2D who visited in the Department of Endocrinology at the Nanjing First Hospital from January 2015 to Aprol 2018. The relationship between levels of SHBG, testosterone and glycemic variation/diabetic complications are analysed.
Conditions
Timeline
- Start date
- 2015-01-01
- Primary completion
- 2018-04-15
- Completion
- 2018-04-20
- First posted
- 2018-05-09
- Last updated
- 2018-05-11
Source: ClinicalTrials.gov record NCT03519529. Inclusion in this directory is not an endorsement.